Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight
PHASE1CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
April 14, 2010
Primary Completion Date
April 28, 2011
Study Completion Date
September 15, 2011
Conditions
Clinical Pharmacology
Interventions
DRUG
Riociguat (Adempas, BAY 63-2521)
0.5 mg riociguat as an immediate-release (IR) tablet
NCT04366622 - Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight | Biotech Hunter | Biotech Hunter